A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year, making it competitive with Eli Lilly & Co. Inc.'s Zepbound. The stock's early-sessions lows ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...